Skip to content

Clinical trials

Phase 3 Metabolic Diseases trials in Italy

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Metabolic Diseases Phase: Phase 3 Country / region: Italy Clear all

12 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20051
20091
20151
20161
20201
20222
20232
20242
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed5
Recruiting3
Terminated3
Active, not recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
89bio, Inc.3
Eli Lilly and Company2
Otsuka Pharmaceutical Development & Commercialization, Inc.2
Calcilytix Therapeutics, Inc., a BridgeBio company1
Ionis Pharmaceuticals, Inc.1
Pfizer1
Takeda1
University of Turin, Italy1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Metabolic Diseases12
Diabetes Mellitus4
Diabetes Mellitus, Type 24
Glucose Metabolism Disorders4
Endocrine System Diseases3
Digestive System Diseases2
Fatty Liver2
Fibrosis2
Hyperlipidemias2
Hypertriglyceridemia2

Trials

Showing 1 to 12 of 12. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.